Following IV hydration and zometa, her calcium normalized, and she underwent treatment with [**Hospital1 **] cycle 1.
Her post-chemo course was unfortunately complicated by DIC requiring multiple cryoprecipitate, C. dif colitis, CMV viremia, and a severe abdominal pain requiring bowel rest with TPN.
She developed a LLL pnuemonia towards the end of her hospitalization and was discharged on a 10 day course of levaquin in addition to home TPN.
Her last hospitalization was complicated by severe abdominal pain requiring bowel rest- she remains on home TPN and has been tolerating light meals due to a sense of fullness.
She had also developed C.dif, and CMV viremia, which had been maintained on PO flagyl x 14d and valganciclovir in the outpatient setting.
She was seen in the internal medicine and dermatology clinics on several occasions and was treated with antibiotics, triamcinolone, clobetasol, and IV triamcinolone w/ no improvement.
PCR analysis for the T-cell receptor gamma gene showed two sharp bands with a migration pattern suggestive of a clonal rearrangement.
- [**9-30**]: Photopheresis therapy through an indwelling central venous catheter, placed due to poor venous access.
- [**2101-1-10**]: Interferon alpha at 3M units 3x/wk given w/ with photopheresis every other week and PUVA.
Photopheresis was d/ced when catheter removed due to a line infection (last treatment [**2101-3-10**]).
Interferon alpha was increased to 6M units three times weekly and bexarotene was started at 150mg daily, decreased to 75mg daily due to poor tolerability.
- [**2101-8-25**]: Mtx added to interferon alpha and bexarotene and the dose was up-titrated to 45mg weekly.
The patient was prescribed vorinostat 400mg daily (started [**2101-10-27**]) with continuation of interferon alpha 6M units TIW.
Due to thrombocytopenia, interferon alpha was decreased to 3M units 3x/wk.
- [**2101-12-22**]: Cycle 1 Day 1 liposomal doxorubicin plus gemcitabine.
- [**2102-2-9**] 3M units TIW Interferon alpha restarted - [**2102-3-9**]: Due to the observation that peripheral T-cells contained floret-like nuclei, immunophenotypic analysis was performed on peripheral blood, revealing findings consistent with involvement by patient's known T cell lymphoproliferative disorder as well as CD25 co-expression in a significant population of the neoplastic CD3+ lymphocytes, suggesting a diagnosis of HTLV-1 associated lymphoma.
- [**2102-5-26**]: Following a treatment break, the patient was started on pentostatin 4mg/m2 weekly x4 doses with reinitiation of interferon alpha at 3Munits 3x/wkly , increased to 3M units 5x/wkly.
She d/ced therapy after 2 cycles in [**7-2**] in favor of a Chinese herbal preparation she received in [**Location (un) 4708**].
- [**2102-12-25**] Initiation of ONTAK therapy Cycle 1 [**2102-12-25**], Cycle 2 [**2103-1-15**], Cycle 3 [**2103-2-5**], Cycle 4 [**2103-2-26**], Cycle 5 [**2103-6-4**], Cycle 6 [**2103-7-2**] - [**2103-4-26**]: 2 weeks of total skin electron beam therapy at the [**Hospital3 2358**] under the care of Dr. [**First Name4 (NamePattern1) 3403**] [**Last Name (NamePattern1) **].
She received a single dose on Friday [**2103-5-25**].
Decision to resume ONTAK therapy with intention of initiating auto-transplant as she demonstrates response.
ET tube tip is in a standard position 3.8 cm above the carina.
Right PICC tip is in the mid SVC.
Left subclavian catheter tip is in the proximal SVC.
NG tube tip is in the stomach.
PORTABLE ABDOMEN [**2103-8-12**]: NG tube tip is in the stomach.
Followup imaging following treatment to ensure resolution is recommended.
However, for evaluation of subtle process, MRI before and after IV gadolinium would be recommended for more sensitive evaluation.
POTASSIUM HYDROXIDE PREPARATION (Final [**2103-9-4**]):       Test cancelled by laboratory.
POTASSIUM HYDROXIDE PREPARATION (Final [**2103-8-29**]):       NO FUNGAL ELEMENTS SEEN.
Immunoflourescent test for Pneumocystis jirovecii (carinii) (Final       [**2103-8-29**]):    NEGATIVE for Pneumocystis jirovecii (carinii)..     FUNGAL CULTURE (Final [**2103-9-14**]):       YEAST.
Test ---- Fungitell (tm) Assay for (1,3)-B-D-Glucans  Results                                 Reference Ranges -------                                 ---------------- 358 pg/mL                               Negative       Less than 60 pg/mL                                         Indeterminate  60 - 79 pg/mL                                         Positive       Greater than or equal to                                                        80 pg/mL       Brief Hospital Course: In brief, Ms. [**Known lastname 4003**] was a 47 year old lady with a diagnosis of HTLV-1 associated Adult T cell leukemia/lymphoma who initially presented with hyerpcalcemia.
She underwent a pulmonary embolization procedure and a second intubation and ICU stay.
Upon returning to the floor, no additional therapeutic intervention was started for her ATLL.
Folic Acid 1 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).
Levothyroxine 100 mcg Tablet Sig: One (1) Tablet PO DAILY (Daily).
Valganciclovir 450 mg Tablet Sig: Two (2) Tablet PO BID (2 times a day).
Metronidazole 500 mg Tablet Sig: One (1) Tablet PO Q8H (every 8 hours).
Lorazepam 0.5 mg Tablet Sig: 1-2 Tablets PO Q4H (every 4 hours) as needed for nausea, anxiety.
Metoclopramide 10 mg Tablet Sig: 0.5 Tablet PO TID (3 times a day).
Doxepin 25 mg Capsule Sig: [**11-25**] Capsules PO once a day.
Spironolactone 25 mg Tablet Sig: Two (2) Tablet PO twice a day.
Pyridoxine 100 mg Tablet Sig: Four (4) Tablet PO once a day.
Fexofenadine 60 mg Tablet Sig: One (1) Tablet PO twice a day.
Allopurinol 300 mg Tablet Sig: One (1) Tablet PO once a day.
Levaquin 750 mg Tablet Sig: One (1) Tablet PO once a day for 9 days.
Line flush order Sodium chloride 5-10ml pre- and post infusion Heparin 10units/ml [**12-29**] ml infused as a final flush 15.
Metoclopramide 5 mg Tablet Sig: One (1) Tablet PO three times a day as needed for nausea.
